A siRNA lipid nanoparticle delivery system targeting lung infection and a preparation method and application thereof

By using an M2 macrophage-targeted lipid nanoparticle delivery system to deliver siRNA-silenced WTAP via tracheal infusion, the problems of insufficient alveolar macrophage targeting and drug-resistant infections in existing technologies are solved, enabling precise treatment of lung infections and enhanced immune function.

CN122124007APending Publication Date: 2026-06-02SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SUN YAT SEN UNIV
Filing Date
2026-03-24
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing technologies lack specific targeting capabilities for alveolar macrophages, research models are disconnected from the real physiological environment, intervention strategies are passive and cannot actively enhance immune function, making it difficult to cope with drug-resistant infections, and systemic administration leads to side effects and insufficient drug concentrations.

Method used

Lipid nanoparticles (LNPs) targeting M2 macrophages are used to deliver siRNA via intratracheal infusion. This siRNA specifically silences WTAP to regulate m6A modification, thereby achieving precise intervention on alveolar macrophages and enhancing their antibacterial and immune functions.

Benefits of technology

It achieves precise targeted treatment of lung infections, avoids systemic side effects, enhances host immune function, effectively combats drug-resistant bacterial infections, and provides a new treatment pathway that does not rely on antibiotics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122124007A_ABST
    Figure CN122124007A_ABST
Patent Text Reader

Abstract

This application relates to the field of biomedical technology, specifically disclosing a siRNA lipid nanoparticle delivery system for treating lung infections, its preparation method, and its application. This application utilizes M2 macrophage-targeting lipid nanoparticles (LNPs) as carriers, delivering WTAP-targeting siRNA to alveolar macrophages via intratracheal instillation. This achieves specific intervention in the m6A methylation modification of alveolar macrophages, thereby actively enhancing the phagocytic clearance, inflammation regulation, and bactericidal functions of AMs, ultimately improving the host's defense against lung bacterial infections (especially drug-resistant bacterial infections).
Need to check novelty before this filing date? Find Prior Art